India's Nicholas Piramal Signs Second Potential $100 Million R&D Deal with Lilly
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - The research unit of Indian firm Nicholas Piramal signed its second development deal with Eli Lilly Feb. 15, worth up to $110 million, to carry out clinical work on two unspecified drugs "directed against the same target" and participate in further studies, manufacturing and sales
You may also be interested in...
Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.
Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.
Analysts Rate Piramal Healthcare Best Play On Innovator CRAMS
MUMBAI - Piramal Healthcare was rated by Citigroup Analysts as India's best play on innovator CRAMS, following its FY09 earnings call July 24